Navigation Links
MIT's PANTHER sensor quickly detects pathogens
Date:3/4/2008

CAMBRIDGE, Mass.--Researchers at MIT Lincoln Laboratory have developed a powerful sensor that can detect airborne pathogens such as anthrax and smallpox in less than three minutes.

The new device, called PANTHER (for PAthogen Notification for THreatening Environmental Releases), represents a significant advance over any other sensor, said James Harper of Lincoln Lab's Biosensor and Molecular Technologies Group. Current sensors take at least 20 minutes to detect harmful bacteria or viruses in the air, but the PANTHER sensors can do detection and identification in less than three minutes.

The technology has been licensed to Innovative Biosensors Inc. (IBI) of Rockville, Md. In January, IBI began selling a product, BioFlash, that uses the PANTHER technology.

There is a real need to detect a pathogen in less than three minutes, so you have time to take action before it is too late, said Harper, the lead scientist developing the sensor.

The PANTHER sensor uses a cell-based sensor technology known as CANARY (after the birds sent into mines to detect dangerous gases), and can pick up a positive reading with only a few dozen particles per liter of air.

The device could be used in buildings, subways and other public areas, and can currently detect 24 pathogens, including anthrax, plague, smallpox, tularemia and E. coli.

There's really nothing out there that compares with this, said Todd Rider of Lincoln Lab's Biosensor and Molecular Technologies Group, who invented the CANARY sensor technology.

Rider started developing CANARY in 1997 when he realized that there were no sensors available that could rapidly detect pathogens. His idea was to take advantage of nature's own defense system-specifically the B cells that target pathogens in the human body. B cells in the body are very fast and very sensitive, Rider said.

The CANARY concept uses an array of B cells, each specific to a particular bacterium or virus. The cells are engineered to emit photons of light when they detect their target pathogen. The device then displays a list of any pathogens found.

CANARY is the only sensor that makes use of immune cells. Other available sensors are based on immunoassays or PCR (polymerase chain reaction), which take much longer and/or are not as sensitive as CANARY.

Rider and colleagues first reported the success of CANARY (which stands for Cellular Analysis and Notification of Antigen Risks and Yields) in the journal Science in 2003. Since then, they have been working to incorporate the technology into a portable device that could be used in a variety of settings where environmental threats might exist.

The new device, PANTHER, takes the CANARY technology and combines it with an air sampler that brings pathogens into contact with the detector cells. The prototype sensor is about a cubic foot and weighs 37 pounds and is well suited to building-protection applications. With minor modifications it could also enhance biological detection capabilities for emergency responders.

CANARY has been tested in rural and coastal environments as well as urban ones. It could eventually be used on farms or in food-processing plants to test for contamination by E. coli, salmonella or other food-borne pathogens.

Another potential application is in medical diagnostics, where the technology could be used to test patient samples, giving rapid results without having to send samples to a laboratory.

Instead of going to the doctor's office and waiting a few days for your test results, with CANARY you could get the results in just a minute or so, said Rider.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Gates Foundation Commits $280 Million for Research to Fight Global TB Epidemic
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
4. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
5. MacArthur commits $11 million to further UCSF work in maternal safety
6. Banco Popular Commits To Make A Difference Day 2007
7. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
8. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
9. Certain Cholesterol Drugs Show Their Limits
10. Gates Foundation Commits to Expansion of HIV Prevention in China
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ANN ARBOR, Mich. (PRWEB) , ... ... ... Global Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing ... the dietary supplement industry. The organization, which plans to publish the first ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: